dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
However, an employer can make a "reasonable" request for employees to work on public holidays, and the employee may only refuse if reasonable, based on factors again including workplace needs, family, overtime rates, and notice. Fourth, there is a right to long service leave which vary by state and award, for instance 2 months paid leave after 10 years in New South Wales.
=== Music videos and other media projects === Phang also directed and wrote a piece entitled Glass Butterfly, a narrative music video featuring intensive visual effects, currently being completed via San Francisco's Studio 400A.
=== Toxicology data === In the 1990s, fialuridine (FIAU) was investigated in clinical trials. The first trial was a 10-day trial in which 43 patients, who were infected with HIV and hepatitis B, demonstrated effective antiviral activity. A subsequent second dose-ranging study was done on 24 patients with hepatitis B over a period of four weeks. The second trial showed significant viral suppression at intermediate doses. However, patients later relapsed, meaning that the viral infection had returned. A longer, 6-month NIH-sponsored, third trial was planned to be conducted, but severe toxicity emerged at patients who had participated in the second trial. Many severe and fatal adverse effects were reported, including lactic acidosis, acute liver failure, peripheral neuropathy, multiple organ failure, and mitochondrial toxicity. A 60-year-old patient died from liver failure and lactic acidosis four months after the second trial. During the third trial, many patients experienced unpleasant side effects such as nausea and vomiting to such an extent that the researchers decided to end the trial. A theory put forward by Dr. Yung-Chi Chang of Yale University in 1991, which hypothesize that FIAU damaged the mitochondrial DNA, thereby giving rise to delayed toxicity. Urgent attempts were subsequently made to counteract the loss of mitochondria. However, by July 16, three patients had died, of whom two had already received a liver transplant and one was waiting for one. By August 1993, two more patients reported to be gravely ill and two other patients had also died.
Irresponsibility on the part of the radioactive material's owners, usually a hospital, university, or military, and the absence of regulation concerning radioactive waste, or a lack of enforcement of such regulations, have been significant factors in radiation exposures. For an example of an accident involving radioactive scrap originating from a hospital, see the Goiânia accident. Transportation accidents involving spent nuclear fuel from power plants are unlikely to have serious consequences due to the strength of the spent nuclear fuel shipping casks. On 15 December 2011, top government spokesman Osamu Fujimura of the Japanese government admitted that nuclear substances were found in the waste of Japanese nuclear facilities. Although Japan did commit itself in 1977 to inspections in the safeguard agreement with the IAEA, the reports were kept secret for the inspectors of the International Atomic Energy Agency. Japan did start discussions with the IAEA about the large quantities of enriched uranium and plutonium that were discovered in nuclear waste cleared away by Japanese nuclear operators. At the press conference Fujimura said: "Based on investigations so far, most nuclear substances have been properly managed as waste, and from that perspective, there is no problem in safety management," but according to him, the matter was at that moment still being investigated.
=== Inhalable insulin === Inhalable insulin, also known as technosphere insulin, is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed. In general, inhaled insulins have been more rapidly absorbed than subcutaneous injected insulin, with faster peak concentration in serum and more rapid metabolism. Exubera, developed by Inhale Therapeutics (later named Nektar Therapeutics), became the first inhaled insulin product to be marketed, in 2006 by Pfizer, but poor sales led Pfizer to withdraw it in 2007. Afrezza, a monomeric inhaled, ultra rapid-acting insulin developed by Mannkind, was approved by the FDA in 2014 and is the only inhaled insulin commercialized as of 2025.
Sources: en.wikipedia.org
=== Detection in body fluids === Nicotine can be quantified in blood, plasma, or urine to confirm a diagnosis of poisoning or to facilitate a medicolegal death investigation. Urinary or salivary cotinine concentrations are frequently measured for the purposes of pre-employment and health insurance medical screening programs. Careful interpretation of results is important, since passive exposure to cigarette smoke can result in significant accumulation of nicotine, followed by the appearance of its metabolites in various body fluids. Nicotine use is not regulated in competitive sports programs.
=== Stem cell expansion === To be used for research or treatment applications, large numbers of high-quality stem cells are needed. Thus, it is necessary to develop culture systems which produce pure populations of tissue-specific stem cells in vitro without the loss of stem-cell potential. Two main approaches are taken for this purpose: two-dimensional and three-dimensional cell culture. Cell culture in two dimensions has been routinely performed in thousands of laboratories worldwide for the past four decades. In two-dimensional platforms, cells are typically exposed to a solid, rigid flat surface on the basal side and to liquid at the apical surface. Inhabiting such a two-dimensional rigid substrate requires a dramatic adaption for the surviving cells because they lack the extracellular matrix that is unique to each cell type which may alter cell metabolism and reduce its functionality. Three-dimensional cell culture systems may create a biomimicking microenvironment for stem cells, resembling their native three-dimensional extracellular matrix (ECM). Advanced biomaterials have significantly contributed to three-dimensional cell culture systems in recent decades, and more unique and complex biomaterials have been proposed for improving stem-cell proliferation and controlled differentiation. Among them, nanostructured biomaterials are of particular interest because they have the advantage of a high surface-to-volume ratio, and they mimic the physical and biological features of natural ECM at the nanoscale.
Vital Brazil was attracted by medical research in the growing fields of bacteriology, virology and immunology at the end of the 19th century, which were being fueled by the great discoveries in Europe, by Louis Pasteur, Robert Koch, Paul Ehrlich and many others. In 1896, when he was still working in Botucatu, Vital Brazil became specially interested in snake incidents and began his studies on snake poisoning, also keeping a scientific collection of snakes stored in alcohol. He therefore returned to São Paulo in 1897 and accepted a position in the Instituto Bacteriológico de São Paulo (Bacteriological Institute of São Paulo), under direction of the great Brazilian pathologist and epidemiologist Adolfo Lutz. There, he worked on the preparation of sera against several diseases, particularly bubonic plague, of which he fell gravely ill, fortunately surviving it. Due to his outstanding work, the government of São Paulo founded a new Serum Therapy Institute in 1901 and gave its directorship to Vital Brazil. He also founded the Institute of Hygiene, Serum Therapy and Veterinary Medicine in the city of Niterói, in 1919, which is called today Vital Brazil Institute (Instituto Vital Brazil). Vital Brazil carried out scientific travels to Europe in 1904 and 1914 and to 1925 to the United States. He continued working at the Butantan Institute for several decades until his retirement in 1919. He died on May 8, 1950, celebrated as one of the most important Brazilian scientists ever.
Meanwhile, the Prince and Princess of Wales release a monochrome photograph of them and their children: Prince George of Wales, Princess Charlotte of Wales, and Prince Louis of Wales. 10 December Lawyers on the right of the Conservative Party describe the new Rwanda legislation as not "sufficiently watertight". In his first broadcast since leaving the post of Immigration Minister, Robert Jenrick tells the BBC Sunak's draft Rwanda law unlikely to work since it is "weak" and will become "bogged down" in legal challenges. The skull of a pliosaur is discovered off the coast of Dorset. The 2 m (6 ft 7 in) fossil is said to have roamed the waters 150 million years ago. A David Attenborough documentary is scheduled to air on BBC One on New Year's Day revealing the "risky mission" of unearthing the "T-Rex of the seas". 11 December The National Crime Agency (NCA) suggests that street drugs stronger than heroin are linked to the deaths of at least 54 people in the past six months, with 40 more cases awaiting further testing. The UK government is offering a £2.5bn financial package for the return of a Stormont Executive, which includes funds to settle public sector disputes and for public services. 12 December The UK government's Safety of Rwanda (Asylum and Immigration) Bill, a piece of emergency legislation to support the Rwanda asylum plan, passes with a majority of 44 as MPs vote 313–269 in favour of it. Dorset Police are investigating following the death of an asylum seeker, thought to have taken his own life, on the accommodation barge Bibby Stockholm.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.